Year :

Legend Biotech Reports Full-Year 2022 Results and Recent Highlights

SOMERSET, N.J.— March 30, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its full year 2022 audited financial results. “2022 was a year of significant milestones for Legend Biotech, marked by the regulatory approvals of CARVYKTI® in the U.S., […]

Mar 30, 2023

Legend Biotech Announces Participation in Upcoming Investor Conferences

SOMERSET, N.J.— February 24, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences: Event: Cowen 43rd Annual Healthcare ConferenceLocation: Boston, MAFireside Chat Date & Time: Tuesday, March 7, 2023 at 9:50am ETPresenter: Ying Huang, […]

Feb 24, 2023

Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2) 

Somerset, N.J.—February 21, 2023—Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced that it received notice from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) on February 17, 2023 indicating that the Company has regained compliance with […]

Feb 21, 2023

Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI®(ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

CARTITUDE-4, the Phase 3 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) compared to standard therapy, has met its primary endpoint.

Jan 27, 2023

Legend Biotech Announces Notification of Delinquency from The Nasdaq Stock Market LLC

Somerset, N.J.—January 10, 2023—Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on January 6, 2023 indicating that the […]

Jan 10, 2023

Thank you for your interest in learning more about Legend Biotech.

Media Relations & Communications

media@legendbiotech.com

close

You are about to leave LegendBiotech.com

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.